Start here
Crisaborole is what I reach for when a parent is frightened of steroids. It is not a strong anti-inflammatory, roughly in the range of a mild steroid, but it can go on eyelids and skin folds and nobody has to count the weeks.
The thing I always warn about is the stinging: a burn for the first few minutes after applying, mostly in the first week, and moisturizing first or keeping the tube in the fridge takes the edge off. It will not catch a bad flare on the body, so I use it to hold skin that is already settled and on the areas I do not want to keep steroids on.
— Dr. Schwarz, Board Certified Dermatologist
Key Facts
−
| Also called | Eucrisa |
| Drug class | Topical PDE4 inhibitor — a non-steroid anti-inflammatory |
| Applied as | 2% ointment |
| Typical course | Twice daily during flares; no limit on total duration |
| Time to work | Some change in the first two weeks, judged at 4 weeks |
| Prescription only | Yes |
What It Is
−
Crisaborole is a prescription ointment approved in 2016 for mild to moderate atopic dermatitis, or eczema. It was first licensed from age two and later down to infants of three months. It is a small boron-containing molecule, unusual in medicine, that blocks an enzyme inside inflammatory cells. Not a steroid, not a calcineurin inhibitor. It does not thin skin, carries no boxed warning, and sets no limit on duration or area.
How It Works
−
Immune cells use a messenger called cyclic AMP as a brake on inflammation. An enzyme, phosphodiesterase-4, breaks it down, and in eczema-prone skin it is overactive, so the brake releases too easily. Crisaborole blocks it, so cyclic AMP stays higher and the cell makes less of the signaling that drives the rash and itch.
The effect is real but modest. In the registration trials the difference between crisaborole and its ointment base was consistent but not large. What the mechanism buys is the safety profile, not raw strength. It acts on immune cells, not the collagen-making cells, so it cannot cause the thinning, stretch marks or visible vessels a strong steroid can over months on delicate skin. The face, the eyelids and the skin folds are where that earns its place.
Here is where Crisaborole (Eucrisa) acts in the skin, and what the others do instead.
About Crisaborole (Eucrisa)
Compare
Skin basics
The redness, swelling and itch are the immune system reacting, not the damage itself. Crisaborole (Eucrisa) turns that reaction down where it is happening, in the skin, which is why a rash settles within days. Not a steroid: it blocks PDE4 inside the cell. For mild eczema, and it can sting.
Crisaborole is small and crosses easily, then breaks down fast in the skin. The stinging some people feel is the price of that speed.
In a plaque, skin cells travel from the bottom of the epidermis to the surface in four to six days instead of a month, and pile up as scale. This slows them back down, so the plaque thins.
The outer film of dead cells and oil. It holds water in and keeps irritants out, and it is thinner than a sheet of paper. Almost every dry, itchy, stinging skin problem starts here.
The outer layer, and the only one anything in a jar reaches. It renews itself constantly: a cell made at the bottom takes about a month to reach the surface and flake off. Most of what a skincare product does, it does here.
The living layer underneath, holding the blood vessels, the nerves and the collagen. It is where lasting change happens and it is hard to reach: most of what is sold for the skin never gets this far.
What It Treats
−

Forms
−
One form only:
A genuine ointment, not a cream:
Strengths
−
One strength. No weaker version for sensitive areas, no stronger one for stubborn ones.
Basics
−
Sample Routine
−
Here is where Crisaborole (Eucrisa) sits in a day, and what goes around it. Pick what you are treating and what your skin is like, and the rest of the routine changes to suit.
What to Expect
−
What to Avoid
−
- Eyes, inside the mouth, and the vagina Skin only. If it gets into an eye, rinse with water.
- Open, weeping, or broken skin Absorption and stinging are both greater there; broken skin needs something else first.
- Treating a widespread flare with it alone Not strong enough for a bad flare across the body. It holds skin better than it rescues.
- Using it instead of moisturizer It is medicine for the inflamed patches. Moisturizer everywhere else still has to happen.
- Wrapping the treated area tightly Occlusion increases absorption, and the base already holds heat.
Monitoring
−
No blood tests and no routine monitoring. Very little reaches the bloodstream, and what does is broken down quickly, so nothing accumulates.
Monitoring is a review at about four weeks to decide whether it is working. Long term, this is a drug people can stay on: no maximum duration, no limit on the area treated, no rest period. That is the practical difference between it and a topical steroid.
The one thing worth watching is whether it is quietly standing in for treatment that would actually control the disease. Eczema that keeps escaping it needs a different plan, not more months of the same ointment.
If You Stop
−
There is no taper, no rebound, no withdrawal. Stop and restart freely: on during flares, off in between. Eczema relapses, so the rash tends to come back when treatment stops, generally within weeks. That is the disease returning, not an effect of stopping this drug. Moisturizer through the gaps is what makes the gaps longer.
Cost
−
Cost is the obstacle here, not safety. It has been brand-name with no stocked generic for most of its life, and the cash price for a large tube is high. Generic availability changes, so ask the pharmacy. Prior authorization is common. Plans usually want a topical steroid first, sometimes a calcineurin inhibitor too, which is cheaper as a generic. A savings card exists for people with commercial insurance, with terms that change often. Tube size matters more than with most creams, because it goes on twice a day over an area. A small tube covering a child's whole body lasts days. Ask for the size that matches the area treated.
Ask Your Doctor
−
How It Compares
−




Myths
+
- "It is a steroid." No. It blocks an enzyme inside inflammatory cells and does nothing to what steroids thin.
- "The stinging means I am allergic to it." Stinging on application is the commonest effect, not allergy, which is uncommon. Stinging that worsens over weeks, or a rash spreading past where you applied, needs looking at.
- "It cannot be used on children." Licensed from three months of age, younger than most eczema drugs.
- "There is a limit to how long you can use it." No. No maximum duration, no maximum area, no rest period.
- "It is as strong as a steroid cream." No, and not sold as one. It is in the range of a mild steroid. Its case is where it can be used, not how hard it hits.
Questions Patients Ask
+
Why does it sting?
Probably the drug itself acting on inflamed skin, not the base. It is the commonest complaint, worst in the first days, and fades within a week.
Can I use it on my eyelids?
Thin skin is where it makes the most sense and it is used there, but not in the eye itself. Keep it off the lid margin.
Is it as good as a steroid cream?
No, it is milder. Its advantage is delicate skin and long stretches without the thinning that limits steroids.
How long can I use it for?
There is no set limit. On during flares, off in between, for as long as it helps.
Can children use it?
It is licensed from three months of age.
Does it work for anything other than eczema?
Licensed for atopic dermatitis. Doctors sometimes use it off-label for other inflammatory rashes, where the evidence is thinner.
References
+
- Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2024. — Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2024
- Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology. 2026. — Journal of the American Academy of Dermatology, 2026
- Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. 2023. — The Journal of allergy and clinical immunology, 2023
- Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. The Cochrane database of systematic reviews. 2024. — The Cochrane database of systematic reviews, 2024
- Zhao S, Hwang A, Miller C, et al. Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review. British journal of clinical pharmacology. 2023. — British journal of clinical pharmacology, 2023
- Howell AN, Ghamrawi RI, Strowd LC, et al. Pharmacological management of atopic dermatitis in the elderly. Expert opinion on pharmacotherapy. 2020. — Expert opinion on pharmacotherapy, 2020
